加用依达拉奉治疗急性椎基底动脉系统脑梗死的临床观察

Clinical Effect of Edaravone Added in Treating Acute Vertebrobasilar Insufficiency

目的观察加用依达拉奉治疗急性椎基底动脉系统脑梗死的临床疗效并探讨其作用机制。方法将68例急性椎基底动脉系统脑梗死患者随机分为治疗组34例和对照组34例。2组均予注射用法舒地尔60mg加入生理盐水100mL中静脉滴注,2次/d;治疗组另加用依达拉奉注射液30mg加入生理盐水250mL中静脉滴注,2次/d,连用14d。治疗开始当日晨及治疗14d次日晨抽取静脉血双抗夹心法检测IL-6,MMP-9,同时行ESS评分。结果 2组在治疗14d后ESS评分均有所改善,IL-6,MMP-9降低,但治疗组更明显(P<0.05)。结论依达拉奉能降低急性椎基底动脉系统脑梗死患者的IL-6,MMP-9水平,有效改善其神经功能。

Objective To observe the clinical effect of Edaravone added in treating actue vertebr-obasilar insufficiency and its mechanism.Methods 68cases of actue vertebrobasilar insufficiency patients were randomly divided into two groups.The control group（34cases）used Fasudil while the treatment group（34cases） used Fasudil and Edaravone.Blood IL-6,MMP-9 were detected by double anti-body Sandwich and neurological impairment were recorded by ESS score in 1st day when treatment began and after the 14d treatment.Results ESS scores in both groups increased,but that in the treatment group was higher than that in the control group（P〈0.05）.The levels of IL-6,MMP-9 in both groups decreased,but that in the treatment group was lower than that in the control group（P〈0.05）.Conclusion Edaravone could decrease the levels of IL-6,MMP-9 in actue vertebrobasilar insufficiency and improve neurological function.